Loading...

GNLX GENELUX CORP Management Changes 8-K Filing

GNLX

GNLX

GENELUX CORP

(GNLX)

2026 8-K

Stock Sale Agreement

Corporate Update

Stock Offering Announced

Trial Results Update

Management Change

Option Price Reduction

Clinical Trial Update

Management Changes

Management Change

Annual Meeting of Stockholders

Disclosure of Corporate Pre...

Corporate Presentation and ...

Entry into Material Definit...

Disclosure of Corporate Pre...

Financial Update

Presentation Availability

Presentation Availability

Management Changes

Product Updates

Other Special Situation

Private Placement of Common...

Appointment of Certain Offi...

Stock Option Repricing and IPO

External Links:

On December 30, 2025, Paul Scigalla resigned as Chief Medical Officer of Genelux Corporation, and Jason Litten was appointed to the role effective January 2, 2026.

AI Assistant

GENELUX CORP

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.